MASARAT Mobility Park Welcomes FPI Gulf as Anchor Tenant for Advanced Automotive Parts Manufacturing
10.2.2026 08:48:00 CET | Business Wire | Press release
MASARAT Mobility Park has entered into a development lease agreement with FPI Gulf to establish an automotive parts manufacturing facility, marking a key milestone in the Park’s development. This agreement strengthens MASARAT Mobility Park’s position as the premier destination for localizing the automotive and mobility value chain in Saudi Arabia.
At the PIF Private Sector Forum 2026, MASARAT Mobility Park announced the signing of a development lease agreement with Fortune Parts Industry Gulf (FPI Gulf), a Joint venture between Thailand based FPI Group and local partner Fuel Autoparts Company. This milestone represents a significant step in the Park’s development and supports the localization of automotive manufacturing in the Kingdom, in line with Vision 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211304060/en/
From left to right: Noppawit Tanadumrongsak, Managing Director of FPI India; Abdulrahman Binmahfooz, Managing Director of FPI Gulf; Tienie Ferreira, CEO of MASARAT Mobility Park; and Muhammed Alshiha, Chairman of MASARAT Mobility Park, during the signing ceremony at the PIF Private Sector Forum 2026 in Riyadh. (Photo: AETOSWire)
Under this agreement, FPI Gulf, a global leader in automotive manufacturing services, will establish an automotive parts factory at MASARAT Mobility Park, located within King Salman Automotive Cluster in King Abdullah Economic City (KAEC), reinforcing the Park’s position as Saudi Arabia’s leading destination for automotive and mobility industries.
The facility will specialize in the production and distribution of automotive components using plastic injection molding, chrome plating, and painting technologies. It will serve both local and international Original Equipment Manufacturers (OEMs), contributing to the strengthening of Saudi Arabia’s automotive supply chain.
Commenting on the announcement, Tienie Ferreira, Chief Executive Officer of MASARAT Mobility Park said: “This agreement underscores the strategic value of MASARAT Mobility Park as a purpose-built destination for automotive manufacturing. Welcoming FPI Gulf as our anchor tenant strengthens the Park’s role in enabling an integrated ecosystem that brings together manufacturing, logistics, and industrial infrastructure in a single location.”
Sompol Tanadumrongsak, Chief Executive Officer of FPI Group and President of Thai Auto-Parts Manufacturing Association (TAPMA), added: “Saudi Arabia represents a strategic growth market for FPI Group, and our collaboration with MASARAT Mobility Park marks an important step in expanding our regional footprint. The Park offers a well-connected, investment-ready platform for establishing advanced manufacturing operations to serve local and regional automotive markets. This initiative reflects our long-term commitment to the Kingdom and our support for localization and capability development.”
This milestone reinforces MASARAT’s role as a leading enabler of automotive localization, supported by integrated industrial and logistics capabilities, advanced infrastructure, multimodal connectivity, and Special Economic Zone incentives. This Partnership underscores the Park’s commitment to attracting global industry players, and accelerating the development of a competitive, localized automotive and mobility value chain.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20260211304060/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom